Glypican-3 (GPC3) is an oncofetal heparan sulfate proteoglycan that is virtually absent from normal adult liver yet re-expressed in the majority of hepatocellular carcinomas, where it supports growth through Wnt/β-catenin signaling. Since its identification as a liver-cancer marker in 2003, GPC3 has become a valuable tissue and serum biomarker: immunohistochemistry helps distinguish hepatocellular carcinoma from benign and cirrhotic lesions, while serum assays complement alpha-fetoprotein to raise diagnostic sensitivity. Beyond diagnosis, GPC3 status tracks tumor differentiation and treatment response, and the protein is an active therapeutic target for antibodies, cell therapies, and imaging. This guide explains GPC3 biology, its role across diagnosis, staging, and monitoring, the platforms that quantify it, and its emerging therapeutic landscape. To support this work, we provide GPC3 quantification reagents, custom protein arrays for cancer-biomarker screening, and tailored array-design services.
Introduction
Hepatocellular carcinoma is among the most common causes of cancer death worldwide, and its prognosis remains poor largely because many cases are found late. Established biochemical markers such as alpha-fetoprotein (AFP) lack the sensitivity to catch small tumors and rise in a substantial fraction of benign liver disease, so the field has long sought complementary markers. A breakthrough came with the recognition that Glypican-3 (GPC3), a gene normally silenced after development, is strongly and specifically re-expressed in hepatocellular carcinoma, where it behaves as a tumor-associated antigen. Because GPC3 is a secreted, cell-surface protein, it can be measured both in tissue and in blood, making it unusually versatile as a biomarker. This guide walks through what GPC3 is, why it is useful in liver cancer, how it is detected, and where it is heading as a therapeutic target.
Molecular Biology and Expression
GPC3 is a glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan of the glypican family. In the fetus it is widely expressed and participates in developmental growth signaling, but in healthy adults it is essentially silent in the liver and most other tissues. In hepatocellular carcinoma, GPC3 is re-induced and presented on the cell surface and shed into the circulation as soluble fragments. Functionally, GPC3 interacts with Wnt/β-catenin signaling and can potentiate tumor-cell growth and survival, which helps explain why its re-expression is not merely a passive marker but is tied to malignant behavior.
The oncofetal pattern is the key to GPC3's usefulness: normal hepatocytes, cirrhotic tissue, and most benign hepatic lesions do not express it, so its presence is strongly suggestive of malignancy. The same oncofetal logic extends beyond the liver—GPC3 is also a marker for entities such as ovarian clear-cell carcinoma and certain germ-cell tumors—but in clinical practice its dominant application is hepatocellular carcinoma.
Figure 1. Glypican 3 structure. (Source: Devan AR, et al. 2024)
Diagnostic and Histological Use
In surgical pathology, GPC3 immunohistochemistry is a workhorse adjunct for distinguishing hepatocellular carcinoma from benign mimics. Studies show GPC3 expression helps separate small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules that can otherwise be diagnostically challenging. Its value is especially notable at the extremes of differentiation: it aids recognition of well-differentiated tumors that can be missed and helps confirm poorly differentiated cases where other markers fade.
In blood, serum GPC3 measured by immunoassay complements AFP. Importantly, the two markers are largely independent—many patients negative for AFP are GPC3-positive—so combined measurement raises sensitivity substantially, with reported panels reaching 82% to 94% detection of hepatocellular carcinoma depending on subtype. A meta-analysis summarizing multiple cohorts concluded that serum GPC3 has modest but real diagnostic value that is strongest when used alongside, not instead of, AFP. GPC3 also helps differentiate hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers, sharpening specificity in complex cases.
Staging, Differentiation, and Treatment Response
Beyond a yes/no cancer signal, GPC3 carries information about tumor biology. Its staining intensity tends to increase as tumors lose differentiation, making it a useful marker for grading and for identifying more aggressive phenotypes. In rare variants such as fibrolamellar hepatocellular carcinoma, GPC3 expression patterns differ from conventional disease and can support the comparison and classification of these tumors.
For treatment monitoring, the most direct evidence comes from early work showing GPC3 detectable in serum before surgery and vanishing afterward in patients who underwent successful resection, hinting at its potential to track residual disease or recurrence (1). Although serum GPC3 alone has not replaced imaging or AFP for surveillance, its dynamics make it a candidate component of multimarker response-assessment panels, particularly when integrated with other tumor-associated antigens on multiplex platforms.
Detection Platforms: Arrays, Assays, and Imaging
GPC3 can be quantified by several orthogonal methods. Tissue expression is read by immunohistochemistry and, increasingly, by image-analysis pipelines that score staining intensity. Soluble GPC3 in serum or plasma is measured with sandwich immunoassays, and the availability of sensitive kits has made longitudinal monitoring practical in preclinical and translational studies.
A distinctive advantage of protein-array technology is the ability to profile many tumor-associated antigens at once. Rather than assaying GPC3 in isolation, custom arrays can combine GPC3 with AFP, other oncofetal proteins, and candidate markers on a single chip, enabling the kind of combinatorial signature that overcomes the limits of any single analyte. This multiplexing logic is exactly what makes arrays attractive for early diagnosis and treatment-response assessment. Separately, GPC3 has been exploited for molecular imaging: engineered anti-GPC3 fragments labeled with zirconium-89 enable positron-emission tomography of hepatocellular carcinoma lesions, translating the marker from the bench into whole-body visualization.
Frequently Asked Questions
Because normal liver, cirrhosis, and most benign lesions do not express GPC3, its presence strongly favors malignancy. It complements alpha-fetoprotein, which misses many small tumors and rises in benign disease, and its independence from AFP lets combined panels detect more cases.
AFP is the traditional serological marker but has limited sensitivity and specificity. GPC3 adds a largely independent signal; the two together reach substantially higher sensitivity than either alone, though GPC3 by itself is not sensitive enough to replace AFP or imaging for screening.
In tissue, by immunohistochemistry that scores staining intensity. In blood, by sandwich immunoassays that quantify soluble GPC3 in serum or plasma. It can also be profiled on multiplex protein arrays alongside other tumor-associated antigens, and imaged in vivo with labeled anti-GPC3 constructs.
Yes. A humanized anti-GPC3 antibody has been tested in a phase I trial in advanced hepatocellular carcinoma, and GPC3 is under investigation through chimeric antigen receptor T cells, antibody-drug conjugates, immunotoxins, and positron-emission tomography imaging agents.
Arrays let a single experiment profile GPC3 together with many other tumor-associated antigens, enabling combinatorial signatures that overcome single-marker limits. Custom designs can target cancer-related antigens for early detection, staging, and treatment-response assessment.
References
- Devan AR, et al. The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential. Eur J Med Res. 2024 Oct 5;29(1):490.
- Hippo Y, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004 Apr 1;64(7):2418-23.
- Shafizadeh N, et al. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008 Aug;21(8):1011-8.
- Sham JG, et al. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma. J Nucl Med. 2014 Dec;55(12):2032-7.
- Tangkijvanich P, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol. 2010 Jan;25(1):129-37.